Phathom Pharmaceuticals, Inc. (PHAT)
6.92
-0.16
(-2.26%)
USD |
NASDAQ |
Oct 02, 16:00
6.85
-0.07
(-1.01%)
Pre-Market: 07:59
Phathom Pharmaceuticals Enterprise Value : 923.63M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 923.63M |
| October 01, 2026 | 936.44M |
| September 30, 2026 | 954.06M |
| September 29, 2026 | 958.86M |
| September 28, 2026 | 958.06M |
| September 25, 2026 | 954.06M |
| September 24, 2026 | 936.44M |
| September 23, 2026 | 928.84M |
| September 22, 2026 | 990.89M |
| September 21, 2026 | 966.07M |
| September 18, 2026 | 968.47M |
| September 17, 2026 | 990.09M |
| September 16, 2026 | 985.28M |
| September 15, 2026 | 1.023B |
| September 14, 2026 | 1.065B |
| September 11, 2026 | 1.039B |
| September 10, 2026 | 1.040B |
| September 09, 2026 | 1.064B |
| September 08, 2026 | 1.125B |
| September 04, 2026 | 1.130B |
| September 03, 2026 | 1.094B |
| September 02, 2026 | 1.111B |
| September 01, 2026 | 1.121B |
| August 31, 2026 | 1.136B |
| August 28, 2026 | 1.105B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.085B |
| August 26, 2026 | 1.072B |
| August 25, 2026 | 1.074B |
| August 24, 2026 | 1.063B |
| August 21, 2026 | 1.080B |
| August 20, 2026 | 1.058B |
| August 19, 2026 | 1.116B |
| August 18, 2026 | 1.110B |
| August 17, 2026 | 1.113B |
| August 14, 2026 | 1.137B |
| August 13, 2026 | 1.105B |
| August 12, 2026 | 1.104B |
| August 11, 2026 | 1.051B |
| August 10, 2026 | 1.056B |
| August 07, 2026 | 1.054B |
| August 06, 2026 | 1.041B |
| August 05, 2026 | 1.029B |
| August 04, 2026 | 1.046B |
| August 03, 2026 | 1.089B |
| July 31, 2026 | 1.070B |
| July 30, 2026 | 1.093B |
| July 29, 2026 | 1.302B |
| July 28, 2026 | 1.303B |
| July 27, 2026 | 1.326B |
| July 24, 2026 | 1.286B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.58M |
| Revenue (Quarterly) | 74.27M |
| Total Expenses (Quarterly) | 91.86M |
| EPS Diluted (Quarterly) | -0.2099 |
| Gross Profit Margin (Quarterly) | 79.68% |
| Profit Margin (Quarterly) | -23.67% |
| Earnings Yield | -18.42% |
| Normalized Earnings Yield | -18.42 |